Corinne Jenkins

Stock Analyst at Goldman Sachs

(1.25)
# 1808
Out of 5,218 analysts
75
Total ratings
43.75%
Success rate
10.48%
Average return
19 Stocks
Name Action Price Target Current % Upside Ratings Updated
Rhythm Pharmaceutica...
Maintains: Strong Buy
59 66
55.28 19.39% 8 Dec 5, 2024
TG Therapeutics
Maintains: Neutral
20 22
32.03 -31.31% 8 Nov 5, 2024
Intra-Cellular Thera...
Maintains: Neutral
77 74
83.02 -10.86% 5 Aug 8, 2024
Fulcrum Therapeutics
Upgrades: Buy
6 15
3.97 277.83% 2 May 14, 2024
IDEAYA Biosciences
Maintains: Buy
53 46
25.19 82.61% 5 May 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
16 18
11.83 52.16% 5 Apr 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
4 5
3.86 29.53% 3 Mar 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reinstates: Neutral
13
8.98 44.77% 3 Jan 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Sell
25 28
32.38 -13.53% 7 Jan 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
47 52
38.38 35.49% 5 Nov 29, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
10 9
n/a n/a 5 Nov 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
332 296
n/a n/a 2 Nov 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
12 4
0.41 875.61% 6 Aug 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
27 23
0.91 2427.47% 2 Mar 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
25 21
3.23 550.15% 2 Mar 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
9 14
6.71 108.64% 2 Dec 20, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Sell
2
n/a n/a 1 Aug 22, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
9 8
17.49 -54.26% 2 May 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
16
0.58 2658.62% 2 Dec 15, 2021